News

After the overturn of Roe V. Wade, states with ban see less than a dozen legal abortions a month.

The FDA orders new warnings for CAR-T cell therapies due to reports of T-cell malignancies, including fatal cases, applying to BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.

Gilead's share price fell 10% today after it announced that Trodelvy, an antibody-drug conjugate, failed to meet its overall survival end point in a trial testing it as treatment for metatstatic non-small cell lung cancer.

Experts from Harvard, Georgetown and Johns Hopkins debate the wisdom of cost sharing in today's JAMA Internal Medicine.

A research team led by University of California, San Francisco, found flaws in how the large language model assessed prevalence and made differential diagnoses.

The FDA approved Dermavant Science's Vtama (tapinarof cream) last year as a treatment for plaque psoriasis. Sales have been disappointing, according to press reports. Will Vtama, which has a different mechanism of action than the current batch of topical medications for atopic dermatitis, fare better in the atopic dermatitis market?

Annual report from the American Cancer Society says HIV is an underlying factor in a handful of cancer diagnoses.

The proportion of cancer patients who are 50-64 is increasing while the proportion of those 65 and older is shrinking, according to American Cancer Society researchers.

Overall cancer mortality in the U.S. continues to decline but there are some worrying trends in incidence and wide racial disparities.

States can use federal money that would otherwise support ACA marketplace premium tax credits to set up programs that offer health insurance to low-income people whose incomes are too high to make them eligible for Medicaid.

The smartphone app is currently under investigation in the CONVOKE study as a pharmaceutical therapy, aiming to address the negative symptoms associated with adult schizophrenia.

A substantial reduction in claim costs can be persuasive and attention-grabbing, but without assurances of continuity of care and proper clinical oversight, the ultimate goal of positive patient health outcomes can be elusive — and costly.

The CAR T-cell therapy targets the CD19 protein ubiquitous on the surface of B cells, which are known to mediate various types of autoimmune diseases, including MS.

UnitedHealth Group executives attribute the increase of revenue at Optum Rx to the addition of new clients, expanded relationships with existing clients, and advancements in services.

UnitedHealth Group executives attribute the increase in revenue and earnings to growth at both its Optum and UnitedHealthcare divisions.

Researchers developed a new multi-cancer blood screening test to detect early-stage cancers and found it had a high level of accuracy.

Janssen Biotech's Remicade (infliximab), an FDA-approved tumor necrosis factor inhibitor since 1998 for Crohn's disease, has gained additional approvals for managing ulcerative colitis and rheumatoid arthritis.

New sign-up rates for plan selections total 18%.

After anticipation of integrating two health systems for the last two years, Essentia Health and Marshfield Clinic Health System (MCHS) recently announced their merger will no longer be in effect.

The transaction is valued at about $575 million. The sale is part of Rite Aid’s restructuring plan after filing for bankruptcy in October 2023.

The Philadelphia-based insurer has selected four winners.

Research findings reported in Health Affairs today show that relatively small increases in out-of-pocket costs for HIV preexposure prophylaxis (PrEP) have a disproportionate effect on the proportion of people who don't get the prescription filled.

Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.